EUVIMEDEUVIMED entdecken
Crossref

Duration of triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A single-center retrospective review

Sarah Emma Berman, Kathleen Ann Lusk, Amanda K. Kitten, Rebecca L. Attridge, Harneal Diocee

American Journal of Pharmacotherapy and Pharmaceutical Sciences · 17.03.2026 · 5 · 9

DOI: 10.25259/ajpps_2026_009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Pharmacotherapy and Pharmaceutical Sciences, online erschienen am 17.03.2026. Verfasst von Sarah Emma Berman und 4 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives: The optimal duration of triple antithrombotic therapy (TAT) consisting of an anticoagulant and dual antiplatelet therapy is unclear in patients with atrial fibrillation (AF) on anticoagulation who require percutaneous coronary intervention (PCI). Guidelines recommend TAT be continued up to 1 week in most patients or up to 1 month in patients at increased thrombotic risk. However, these recommendations are based on expert opinion due to the lack of randomized controlled trials directly comparing TAT duration. The purpose of this study was to evaluate the optimal duration of TAT in patients with AF following PCI. Materials and Methods: This study was a single-center, retrospective cohort study. Subject cohorts were determined based on TAT duration of

Zitieren

APA

Berman, S. E., Lusk, K. A., Kitten, A. K., Attridge, R. L., & Diocee, H. (2026). Duration of triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A single-center retrospective review. American Journal of Pharmacotherapy and Pharmaceutical Sciences, 5, 9. https://doi.org/10.25259/ajpps_2026_009

Vancouver

Berman SE, Lusk KA, Kitten AK, Attridge RL, Diocee H. Duration of triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A single-center retrospective review. American Journal of Pharmacotherapy and Pharmaceutical Sciences. 2026;5:9. doi:10.25259/ajpps_2026_009

BibTeX
@article{Berman2026,
  author = {Berman, Sarah Emma and Lusk, Kathleen Ann and Kitten, Amanda K. and Attridge, Rebecca L. and Diocee, Harneal},
  title = {Duration of triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A single-center retrospective review},
  journal = {American Journal of Pharmacotherapy and Pharmaceutical Sciences},
  year = {2026},
  volume = {5},
  pages = {9},
  doi = {10.25259/ajpps_2026_009}
}
Kostenlos starten →